Herbert Lee, Jr. v. Gloria Thompson

CourtMississippi Supreme Court
DecidedJanuary 31, 2008
Docket2008-CA-01932-SCT
StatusPublished

This text of Herbert Lee, Jr. v. Gloria Thompson (Herbert Lee, Jr. v. Gloria Thompson) is published on Counsel Stack Legal Research, covering Mississippi Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Herbert Lee, Jr. v. Gloria Thompson, (Mich. 2008).

Opinion

IN THE SUPREME COURT OF MISSISSIPPI

NO. 2008-CA-01932-SCT

HERBERT LEE, JR.

v.

GLORIA THOMPSON AND DEBORAH DIXON

DATE OF JUDGMENT: 01/31/2008 TRIAL JUDGE: HON. BOBBY BURT DELAUGHTER COURT FROM WHICH APPEALED: HINDS COUNTY CIRCUIT COURT ATTORNEY FOR APPELLANT: LEONARD McCLELLAN ATTORNEY FOR APPELLEES: LANCE L. STEVENS NATURE OF THE CASE: CIVIL - CONTRACT DISPOSITION: ON DIRECT APPEAL: AFFIRMED AND REMANDED. ON CROSS-APPEAL: REVERSED AND REMANDED - 09/09/2010 MOTION FOR REHEARING FILED: MANDATE ISSUED:

BEFORE WALLER, C.J., LAMAR AND PIERCE, JJ.

PIERCE, JUSTICE, FOR THE COURT:

¶1. This appeal arises from the trial court’s grant of summary judgment in an action

between an attorney and his former clients. Gloria Thompson and Deborah Dixon sued

attorney Herbert Lee, Jr., who represented them in diet-drug litigation, for breach of contract,

tortious breach of contract, failure to accurately refund their portion of a multi-district

litigation fee, and under the theory of quantum meruit. The trial court granted partial

summary judgment to the plaintiffs and partial summary judgment to the defendant. Both

parties appeal. FACTS

¶2. Gloria Thompson and Deborah Dixon (collectively referred to as “the plaintiffs”)

hired attorney Herbert Lee, Jr., to represent them in diet-drug litigation (commonly referred

to as Fen/Phen claims) against the diet-drug manufacturer, American Home Products

(“AHP”). They were among thirteen plaintiffs who hired Lee to represent them in the diet

drug suit against AHP on a contingency-fee basis. The parties dispute whether the

contingency fee agreed to was forty percent or forty-five percent.

¶3. The diet-drug lawsuit was filed on behalf of the thirteen plaintiffs in the Circuit Court

of Holmes County, Mississippi, and settled for an aggregate amount of approximately $32

million. As part of the settlement, a Multi District Litigation 1203 1 (“MDL 1203”) assessment

1 MDL 1203: United States Courts' Multidistrict Litigation, Action No. 1203, In Re: Diet Drugs “consolidates, for pretrial purposes, all federal litigation relating to use of the diet drugs Phentermine, Fenfluramine, and Dexfenfluramine. Collectively, these drugs are commonly referred to as ‘Fen/Phen’.” www.fenphen1203.com. “Any action pending in any state court which relates to the personal injuries allegedly caused by the [Fen/Phen drugs] is eligible for State-Federal coordination.” MDL 1203 Pretrial Order No. 467. (Feb. 10, 1999). The history of MDL 1203 is as follows:

From 1989 through September, 1997, Wyeth marketed and sold two prescription drugs for weight loss in the United States under the brand names Pondimin (fenfluramine) and Redux (dexfenfluramine) (hereinafter “diet drugs”). Beginning in 1992, physicians commonly prescribed Pondimin in combination with phentermine, another prescription diet drug. Phentermine was and still is distributed and sold under several different brand names. The combination of Pondimin with phentermine was often referred to as “fen-phen.” Wyeth had significant sales of both Pondimin and Redux in the mid-1990's. From January, 1995 until mid-September, 1997, approximately four million persons in the United States took Pondimin. Similarly, from June, 1996 through September, 1997, two million people in this country used Redux. During the period from March to August, 1997 the Mayo Clinic in Rochester, Minnesota observed and reported an association between the use of fenfluramine and/or dexfenfluramine and valvular heart disease (“VHD”). On September 15, 1997, Wyeth and the Food and Drug Administration (“FDA”) announced that there would be no further sales of Pondimin and Redux in the United States. Since that time, epidemiological studies have established a causal relationship between fenfluramine and dexfenfluramine and VHD. These studies have also determined that fenfluramine and dexfenfluramine cause a fatal but rare disease known as primary pulmonary hypertension (“PPH”). A tidal wave of litigation followed the withdrawal of Pondimin and Redux. Individuals who had ingested diet drugs filed lawsuits and class actions in federal and state

2 fee of six percent of the total settlement was withheld and sent to the MDL 1203 Fee and Cost

Account. The six percent fee resulted from Lee contracting with the Plaintiffs’ Management

Committee (“PMC”) of MDL 1203 to provide he and his clients certain “common benefit”

discovery material.

¶4. Both plaintiffs signed disclosure sheets documenting the disbursal of funds prior to

receiving their portion of the settlement. They allege they were coerced by Lee into signing

the disclosure sheet. Thompson received the largest settlement award of Lee’s thirteen diet-

courts against Wyeth and other defendants, including manufacturers, distributors, weight-loss clinics, pharmacies and physicians. On December 10, 1997, the Judicial Panel on Multidistrict Litigation (the “JPML”) designated the United States District Court for the Eastern District of Pennsylvania as the transferee court for IN RE: DIET DRUGS (PHENTERMINE/FENFLURAMINE/DEXFENFLURAMINE) PRODUCTS LIABILITY LITIGATION, MDL 1203 (“MDL 1203”). See 28 U.S.C. § 1407. All cases filed in the federal judicial system were subsequently transferred to the Eastern District of Pennsylvania for coordinated and consolidated pretrial proceedings. To date, at least 105,000 plaintiffs have filed lawsuits, over 130 class actions were transferred to the MDL and the claims of more than 35,000 plaintiffs have been transferred by the JPM L to [the Eastern District of Pennsylvania]. Shortly after the first transfer of cases to MDL 1203, the court established the Plaintiffs' Management Committee (“PMC”) to oversee the coordinated and consolidated pretrial proceedings and to conduct discovery of widespread applicability on behalf of plaintiffs in MDL 1203. . . .As part of its duties and responsibilities, the PMC assisted and continues to assist all plaintiffs in MDL 1203 and state-federal coordinated proceedings by appearing frequently before [the United States District Court for the Eastern District of Pennsylvania], attending regular status conferences held by the Special Discovery Master, . . . preparing motions and responses regarding case-wide discovery matters and other pretrial issues, and maintaining a document depository for all documents produced in MDL 1203. The PM C was also charged with establishing a Discovery Committee, which consisted of PMC members as well as additional lawyers representing plaintiffs in various state courts. . . . The PMC Discovery Committee coordinated and completed numerous depositions of defendants' corporate representatives, employees and generic experts. The court permitted the PMC and the co-chairs of the PMC Discovery Committee to assign work to other “common benefit” attorneys.

In re: Diet Drugs (Phentermine, Fenfluramine, Dexfenfluramine) Products Liability Litigation, 553 F. Supp. 2d 442, 449-50 (E.D. Pa. 2008).

3 drug clients, more than $7.4 million. Dixon received the third largest settlement award, which

was more than $3.1 million.

¶5. More than a year after the settlement of the plaintiffs’ cases against AHP, the trustee

of the MDL 1203 fund made a determination that one-third of all the sums deposited into the

MDL 1203 Fee and Cost Account should be returned to those who had contributed them

through a process approved by the MDL trustee’s office. Consequently, two percent of Lee’s

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Showa Denko
953 F.2d 162 (Fourth Circuit, 1992)
Turner v. Wakefield
481 So. 2d 846 (Mississippi Supreme Court, 1985)
Channel v. Loyacono
954 So. 2d 415 (Mississippi Supreme Court, 2007)
Waggoner v. Williamson
8 So. 3d 147 (Mississippi Supreme Court, 2009)
Edmonds v. Williamson
13 So. 3d 1283 (Mississippi Supreme Court, 2009)
Singer v. Tatum
171 So. 2d 134 (Mississippi Supreme Court, 1965)
Daniels v. GNB, Inc.
629 So. 2d 595 (Mississippi Supreme Court, 1993)
Germany v. Denbury Onshore, LLC
984 So. 2d 270 (Mississippi Supreme Court, 2008)
Mantachie Nat. Gas v. Miss. Valley Gas Co.
594 So. 2d 1170 (Mississippi Supreme Court, 1992)
In Re Zyprexa Products Liability Litigation
467 F. Supp. 2d 256 (E.D. New York, 2006)
Stoner v. Marshall
358 P.2d 1021 (Supreme Court of Colorado, 1961)
United States Fidelity and Guaranty Co. of Mississippi v. Martin
998 So. 2d 956 (Mississippi Supreme Court, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
Herbert Lee, Jr. v. Gloria Thompson, Counsel Stack Legal Research, https://law.counselstack.com/opinion/herbert-lee-jr-v-gloria-thompson-miss-2008.